Cancer Vaccines
Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future
CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation
Merck Suspends Gardasil Shipments to China, Lowers 2025 Revenue Forecast
Merck, Gardasil, China, revenue forecast, cancer vaccine, shipment suspension
Transgene Faces Setback with Mid-Stage Failure of Cancer Vaccine Candidate
Transgene, cancer vaccine, mid-stage failure, pipeline setback, oncology research
Gritstone Bio Files for Chapter 11 Bankruptcy, Casting Uncertainty Over Cancer Vaccine Development
Gritstone Bio, Chapter 11 bankruptcy, cancer vaccine, financial restructuring, clinical trials, immunotherapy, vaccine development.
Gritstone’s GRANITE Vaccine Shows Encouraging but Limited Benefit in Metastatic Colorectal Cancer
Gritstone bio, GRANITE, cancer vaccine, metastatic colorectal cancer, MSS-CRC, neoantigen targeting immunotherapy, progression-free survival, ctDNA
Gritstone Bio Explores Strategic Alternatives Amid Financial Strains and Mixed Cancer Vaccine Trial Results
Gritstone Bio, GRANITE, cancer vaccine, strategic alternatives, financial challenges, Phase 2 trial results
IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck
IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy
Ultimovacs Cancer Vaccine Faces Significant Challenges After Third Consecutive Failure
Ultimovacs, cancer vaccine, phase 2 trial, clinical failure, financial struggles, biotechnology
Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda
Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program